Health Condition 1: E118- Type 2 diabetes mellitus with unspecified complications
Conditions
Interventions
Intervention1: NIL: NIL
Sponsors
JIPMER Intramural Fund
Eligibility
Inclusion criteria
Inclusion criteria: Cases Patients started on metformin and glimepiride therapy who are on a stable drug regimen for at least 6 months and reached the maximum tolerated dose and or required other addon antidiabetic drug and their Hb1Ac cutoff more than equal to 8 Patients with type 2 diabetes mellitus of South Indian origin. South Indian origin is defined as patients with history of three generations living in any of the southern states namely Puducherry Tamil Nadu Kerala Karnataka Andhra Pradesh and Telangana and speaking the respective local language as mother tongue Both male and female gender Age 30 years and above Controls Patients who are on a stable drug regimen for at least 6 months started on metformin and glimepiride and reached the maximum tolerated dose and other addon antidiabetic drug in addition to above two drugs and their Hb1Ac less than 8 Patients with type 2 diabetes mellitus of South Indian origin. South Indian origin is defined as patients with history of three generations living in any of the southern states namely Puducherry Tamil Nadu Kerala Karnataka Andhra Pradesh and Telangana and speaking the respective local language as mother tongue Both male and female gender Age 30 years and above
Exclusion criteria
Exclusion criteria: Cases Patients with a history of clinically proven renal or hepatic impairment Patients taking cationic medications like cimetidine furosemide nifedipine Drugs inhibiting CYP2C9 like Ketoconazole Phenytoin Amiodarone Fluoxetine Drugs enhancing CYP2C9 Rifampicin Carbamazepine Primidone Pregnancy and lactation Patients who regularly consume alcohol Patients who diagnosed to have type 1 diabetes, maturity onset diabetes of the young and secondary causes due to endocrinopathies or chronic intake of steroidal drugs Controls Patients with a history of clinically proven renal or hepatic impairment Patients taking cationic medications like cimetidine furosemide nifedipine Drugs inhibiting CYP2C9 like Ketoconazole Phenytoin Amiodarone Fluoxetine Drugs enhancing CYP2C9 like Rifampicin Carbamazepine Primidone Pregnancy and lactation Patients who regularly consume alcohol Patients who diagnosed to have type 1 diabetes or maturity onset diabetes of the young and secondary causes due to endocrinopathies chronic intake of steroidal drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To study the association between SLC22A1 GG and CYP2C9 1075 AA genotypes and poor response to metformin glimepiride combined therapy in Type 2 Diabetes Mellitus patients of south Indian originTimepoint: This will be assessed at baseline. | — |
Secondary
| Measure | Time frame |
|---|---|
| To study the effect of combined gene gene interaction of SLC22A1 480 C to G & SLC22A1 rs622342 & CYP2C93 1075 A to C affecting dose requirement of metformin & glimepiride combination therapyTimepoint: Thus will be done 6 months after the beginning of patient recruitment. | — |
Countries
India
Contacts
Public ContactAditya V Reddy
Jawaharlal institute of post graduate medical education and research Puducherry
Outcome results
None listed